Clinical Trials
60 trialsNCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT07490262 2026-04-16
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3 Recruiting
NCT07392866 2026-02-09
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2/3 Not yet recruiting
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06741020 2025-05-23
HAICI
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT04251715 2025-04-18
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06041477 2024-08-27
HAIC
Sun Yat-sen University
Phase 3 Recruiting
NCT06349044 2024-08-27
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Zhejiang Cancer Hospital
Phase NA Recruiting
NCT06201065 2024-01-11
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT05976568 2023-08-04
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05718492 2023-02-08
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
Sun Yat-sen University
Phase NA Recruiting
NCT05617430 2022-11-15
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05517239 2022-08-26
PEACH
Yonsei University
Phase 2 Completed
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05231382 2022-05-24
Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT04595864 2021-11-05
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Recruiting
NCT04994236 2021-08-13
Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02129322 2021-02-15
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Phase 2 Withdrawn
NCT04521491 2020-08-20
A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
Eastern Hepatobiliary Surgery Hospital
Phase NA Unknown
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT03578874 2020-04-09
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
The University of Hong Kong
Phase 2 Completed
NCT02774187 2019-12-05
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT00941655 2019-11-13
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02436044 2019-08-20
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
Sun Yat-sen University
Approved for marketing
NCT00941967 2019-07-10
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT02527772 2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02534337 2019-06-04
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02585479 2019-06-04
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT03812770 2019-04-17
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
Sun Yat-sen University
Phase 2 Unknown
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03468231 2018-03-16
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown
NCT02089633 2017-07-28
PACOX
Bio-Cancer Treatment International Limited
Phase 2 Completed
NCT00483405 2017-07-12
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00861783 2017-06-23
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
Phase 1 Completed
NCT03192618 2017-06-20
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
Phase 3 Unknown
NCT03192644 2017-06-20
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
Phase 3 Unknown
NCT01229111 2017-03-29
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01313377 2017-01-25
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
UNICANCER
Phase 3 Completed
NCT02987699 2016-12-28
Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil
Sun Yat-sen University
Phase 2 Unknown
NCT02403544 2016-01-05
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
ChineseAMS
Phase 1 Unknown
NCT02426450 2015-04-27
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC
Sun Yat-sen University
Phase 2 Unknown
NCT00142467 2014-03-18
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00003427 2013-06-26
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00052364 2013-06-18
Oxaliplatin in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00274885 2011-12-05
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
National Cancer Institute (NCI)
Phase 4 Unknown